GSK: Getting Better?

A report on GlaxoSmithKline’s policy and performance in such areas as environmental management, community relations, lobbying, advertising and the pricing of drugs in developing countries. Key findings and issues:

• GSK is relatively transparent on many issues
• questions raised about company reporting and other practices of interest to investors
• the need for increased site-level information
• greater transparency desirable in relation to corporate lobbying, particularly over international regulation of intellectual property
• clarification requested on the company’s preferential pricing schemes for developing countries
• analysis based on the Bench Marks
  
• GSK’s full written response to the report and questions posed is included.
  

Published 2004. Hard copy: ECCR members - £8 / €9 / $13. Non-members - £16 / €18 / $26. Order form.

Download a copy of the full report (pdf).